Get the Stockscreener App
1.87
4.59%
-0.09
Ocugen Inc stock is traded at $1.87, with a volume of 6.21M.
It is down -4.59% in the last 24 hours and up +2.75% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.96
Open:
$1.95
24h Volume:
6.21M
Relative Volume:
0.83
Market Cap:
$613.17M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-8.2817
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-8.33%
1M Performance:
+2.75%
6M Performance:
+28.08%
1Y Performance:
+158.32%
1-Day Range:
$1.86
$1.96
1-Week Range:
$1.79
$2.29
52-Week Range:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.87 | 613.17M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Completes Enrollment For Phase 3 Trial - Let's Data Science
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen - Stock Titan
Can Ocugen succeed where other gene therapy makers have struggled? - pharmavoice.com
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies - TipRanks
What is Noble Financial's Estimate for Ocugen Q3 Earnings? - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen Earnings - MarketBeat
Ocugen posts investor presentation outlining progress across three gene-therapy BLAs, Phase 3 enrollment and positive Phase 2/3 data - tradingview.com
Ocugen (OCGN) showcases retinal gene therapy pipeline with new OCU410 Phase 2 data - Stock Titan
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen (NASDAQ:OCGN) Given "Buy" Rating at Chardan Capital - MarketBeat
Ocugen (OCGN) Stock Maintained at Buy Rating by Chardan Capital - GuruFocus
Ocugen Shares Drop as Eye Disease Gene Therapy Shows Delays in Phase II Trial - Bitget
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail
Noble Capital raises Ocugen stock price target on phase 2 results By Investing.com - Investing.com Australia
Noble Capital raises Ocugen stock price target on phase 2 results - Investing.com UK
H.C. Wainwright raises Ocugen stock price target on gene therapy data - Investing.com India
Ocugen Lines Up Phase III Macular Degeneration Study For Gene Therapy OCU410 - Citeline News & Insights
OCGN: HC Wainwright & Co. Raises Price Target to $10.00, Maintai - GuruFocus
Ocugen’s GA gene therapy garners mixed sentiments on 12-month Phase II readout - Yahoo Finance
H.C. Wainwright raises Ocugen stock price target on gene therapy data By Investing.com - Investing.com Australia
HC Wainwright Increases Ocugen (NASDAQ:OCGN) Price Target to $10.00 - MarketBeat
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Sahm
10 best high-risk penny stocks to buy right now - MSN
Ocugen Gains $15 Million, Extends Cash Runway to 2027 - TipRanks
why-did-dpro-stock-crash-after-hours-today - Stocktwits
Ocugen (OCGN) Has A Healthy Cash Position For 2026 - Insider Monkey
Ocugen (OCGN) Shares Tumble After Phase 2 Trial Data Release - GuruFocus
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months - MarketBeat
Ocugen (NASDAQ:OCGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Ocugen’s Tumultuous Chapter: Earnings, Strategies, and Market Reactions - StocksToTrade
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Reports Positive Phase 2 Data for OCU410 Therapy - TipRanks
Ocugen’s Strategic Directions Amid Economic Challenges - timothysykes.com
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (NASDAQ: OCGN) reports strong Phase 2 OCU410 results in geographic atrophy - Stock Titan
OCU410 Phase II data show significant reduction in lesion size at 12 months - thepharmaletter.com
Ocugen falls after 12-month data from mid-stage trial for GA therapy - MSN
Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA - Traders Union
Ocugen stock falls 5% despite positive gene therapy trial data - Investing.com
Ocugen (OCGN) Reports Promising Phase 2 Results for Gene Therapy OCU410 - GuruFocus
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce? - Stocktwits
Ocugen stock falls on trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 31% lesion reduction in gene therapy trial By Investing.com - Investing.com Canada
Ocugen reports 31% lesion reduction in gene therapy trial - Investing.com
OCGN: OCU410 reduced lesion growth by 31% at 12 months in Phase 2, with no serious safety issues - TradingView
Ocugen, Inc. Reports Phase 2 Results for OCU410 Showing 31% Reduction in Geographic Atrophy Lesion Growth After 12 Months - Quiver Quantitative
One-shot gene therapy cut eye-lesion growth 31% in dry AMD trial - Stock Titan
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.03%
2.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):